

7. Literaturverzeichnis

1. Hendrickson B, Gokhale R, Cho J. *Clinical aspects and pathophysiology of inflammatory bowel disease*. Clin Microbiol Rev 2002; 15, 1: 79-94.
2. Parronchi P, Romagnani P; Annunziato F, et al. *Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease*. Am J Pathol 1997; 150: 823-832.
3. Komatsu M, Kobayashi D, Saito K, et al. *Tumour necrosis factor alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive Immuno-PCR*. Clin Chem 2001; 47, 7: 1297-1301.
4. Targan SR, Hanauer SB, van Deventer SJ, et al. *A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease*. N Engl J Med 1997; 337: 1029-1035.
5. Present DH, Rutgeerts P, Targan S, et al. *Infliximab for the treatment of fistulas in patients with Crohn's disease*. N Engl J Med 1999; 340: 1398-1405.
6. Keane J, Gershon S, Wise RP et al. *Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent*. N Engl J Med 2001; 345: 1098-1104.
7. Garcia-Planella E, Domenech E, Esteve-Comas M, et al. *Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab)*. Eur J Gastroenterol Hepatol 2003; 15, 4: 351-354.
8. Baert F, Noman M, Vermeire S, et al. *Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease*. N Engl J Med 2003; 348, 7: 601-608.
9. Sabate JM, Villarejo J, Lemann M, et al. *An open-label trial study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease*. Aliment Pharmacol Ther 2002; 16, 6: 1117-1124.
10. Kanai T, Watanabe M, Okazawa A, et al. *Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease*. Gastroenterology 2000; 119: 1514-1523.

11. Pizarro T, Michie M, Bentz M, et al. *IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells.* J Immunol 1999; 162: 6829-6835.
12. Liesenfeld O, Kosek J, Remington JS, Suzuki Y. *Association of CD4+ T cell-dependent, interferon- γ -mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii.* J Exp Med 1996; 184: 597-607.
13. Liesenfeld O, Kang H, Park D, et al. *TNF- α , nitric oxide and IFN- γ are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii.* Parasite Immunol 1999; 21: 365-376.
14. Suzuki Y, Sher A, Yap G, et al. *IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii.* J Immunol 2000; 164: 5375-5382.
15. Liesenfeld O. *Oral infection of C57BL/6 mice with Toxoplasma gondii: A new model of inflammatory bowel disease?* JID 2002; 185 (Suppl 1): S96-101.
16. Mordue D, Monroy F, La Regina M, et al. *Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines.* J Immunol 2001; 167: 4574-4584.
17. Okamura H, Tsutsui H, Komatsu T, et al. *Cloning of a new cytokine that induces IFN- γ production by T cells.* Nature 1995; 378: 88-91.
18. Ghayur T, Banerjee S, Hugunin M, et al. *Caspase-1 processes IFN- γ -inducing factor and regulates LPS-induced IFN- γ production.* Nature 1997; 386: 619-623.
19. Stoll S, Jonuleit H, Schmitt E, et al. *Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development.* Eur J Immunol 1998; 28: 3231-3239.
20. Stoll S, Muller G, Kurimoto M, et al. *Production of IL-18 (IFN- γ -inducing factor) messenger RNA and functional protein by murine keratinocytes.* J Immunol 1997; 159: 298-302.

21. Takeuchi M, Nishizaki Y, Sano O, et al. *Immunohistochemical and immunoelectron-microscopic detection of interferon- γ -inducing factor (interleukin-18) in mouse intestinal epithelial cells*. Cell Tissue Res 1997; 289: 499-507.
22. Cameron LA, Taha RA, Tsicopoulos A, et al. *Airway epithelium expresses interleukin-18*. Eur Respir J Immunol 1999; 14: 553-559.
23. Udagawa N, Horwood NJ, Elliott J, et al. *Interleukin-18 (interferon γ -inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon- γ to inhibit osteoclast formation*. J Exp Med 1997; 185: 1005-1012.
24. Wu C-Y, Maeda H, Contursi C, et al. *Differential requirement of IFN consensus sequence binding protein for the production of IL-12 and induction of Th1-type cells in response to IFN- γ* . J Immunol 1999; 162: 807-812.
25. Kim Y-M, Kang H-S, Paik S-G, et al. *Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression*. J Immunol 1999; 163: 2000-2007.
26. Debets R, Timans J Immunol, Churakawo T, et al. *IL-18 receptors, their role in ligand binding and function: anti-IL-1RacPL antibody, a potent antagonist of IL-18*. J Immunol 2000; 165: 4950-4956.
27. Robinson D, Shibuya K, Mui A, et al. *IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAk and NF- κ B*. Immunity 1997; 7: 571-581.
28. Barbulescu K, Becker C, Schlaak J, et al. *IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN- γ promoter in primary CD4+ T lymphocytes*. J Immunol 1998; 160: 3642-3647.
29. Yoshimoto T, Takeda K, Tanaka T, et al. *IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells and B cells: synergism with IL-18 for IFN- γ production*. J Immunol 1998; 161: 3400-3407.
30. Tomura M, Zhou XY, Maruo S, et al. *A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells*. J Immunol 1998; 160: 4738-4746.
31. Yoshimoto T, Okamura H, Tagawa YI, et al. *Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon- γ production from activated B cells*. Acad Sci Proc Natl USA 1997; 94: 3948-3953.

32. Munder M, Mallo M, Eichmann K, et al. *Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation.* J Exp Med 1998; 187: 2103-2108.
33. Fukao T, Matsuda S, Koyasu S, et al. *Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN- γ production by dendritic cells.* J Immunol 2000; 164: 64-71.
34. Komai-Koma M, Alastair Gracie J, Wei X et al. *Chemoattraction of human T cells by IL-18.* J Immunol 2003; 170: 1084-1090.
35. Takeda K, Tsutsui H, Yoshimoto T, et al. *Defective NK cell activity and Th1 response in IL-18-deficient mice.* Immunity 1998; 8: 383-390.
36. Okamoto I, Kohno K, Tanimoto T, et al. *Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12.* J Immunol 1999; 162: 3202-3211.
37. Neighbors M, Xu X, Barrat FJ. *A critical role for IL-18 in primary and memory responses to Listeria monocytogenes that extends beyond its effects on interferon γ production.* J Exp Med 2001; 194: 343-354.
38. Hofstra CL, Van Al, Hofman G, et al. *Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia and serum IgE levels.* J Immunol 1998; 161: 5054-5060.
39. Wild JS, Sigounas A, Sur N, et al. *IFN- γ -inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines and airway eosinophilia in mouse model of allergic asthma.* J Immunol 2000; 164: 2701-2710.
40. Gracie J, Forsey R, Chan W, et al. *A proinflammatory role for IL-18 in rheumatoid arthritis.* J Clin Invest 1999; 104: 1393-1401.
41. McGuinness P, Painter D, Davies S, et al. *Increases in intrahepatic CD68 positive cells, MAC387 positive cells and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection.* Gut 2000; 46: 260-269.
42. Shigehara K, Shijubo N, Ohmichi M, et al. *IL-12 and IL-18 are increased and stimulate IFN- γ production in sarcoid lungs.* J Immunol 2001; 166: 642-649.

43. Siegmund B. *Interleukin-1 β converting enzyme (caspase-1) in intestinal inflammation*. *Biochem Pharmacol* 2002; 64: 1-8.
44. Siegmund B, Fantuzzi G, Rieder F, et al. *Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN- γ and TNF- α production*. *Am J Physiol Regul Integr Comp Physiol* 2001; 281: R1264-1273.
45. Kanai T, Wanatabe M, Okazawa A, et al. *Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease*. *Gastroenterology* 2001; 121: 875-888.
46. Ten Hove T, Corbaz A, Amitai H, et al. *Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF- α production in mice*. *Gastroenterology* 2001; 121: 1372-1379.
47. Wirtz S, Becker C, Blumberg R, et al. *Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA*. *J Immunol* 2002; 168: 411-420.
48. Lochner M, Wagner H, Classen M, Forster I. *Generation of neutralizing mouse anti-mouse IL-18 antibodies for inhibition of inflammatory responses in vivo*. *J Immunol Methods* 2002; 259:149-157.
49. Sugawara I, Yamada H, Kaneko H, et al. *Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene disrupted mice*. *Infect Immun* 1999; 67, 5: 2585-2589.
50. Lu H, Takeda K, Zhang D, et al. *Chlamydia trachomatis mouse pneumonitis lung infection in IL-18 and IL-12 knockout mice: IL-12 is dominant over IL-18 for protective immunity*. *Mol Med* 2000; 6: 604-612.

Teile der vorliegenden Dissertation sind als Paper zur Veröffentlichung im European Journal of Immunology eingereicht.